- IND filing for HPK1 inhibitor ‘IN-122517’ planned for 2026
- Dong-A ST and 에볼루션 바카라 inno.N co-develop targeted lung cancer treatment ‘IN-207039’
[by Yu, Suin] HK inno.N announced on April 29 that it participated in the American Association for Cancer Research (AACR 2025), held in Chicago, USA from April 25 to 30 (local time), where it presented research findings on two novel anticancer drug candidates.
The presentation highlighted research findings on ‘IN-122517 (development code)’, a HPK1 inhibitor gaining attention as a next-generation immuno-oncology drug, and ‘IN-207039 (development code, Dong-A ST development code SC2073)’, a selective degrader targeting epidermal growth factor receptor (EGFR) mutations for the treatment of non-small cell lung cancer. Among them, the EGFR degrader is being co-developed by 에볼루션 바카라 inno.N and Dong-A ST.
IN-122517, a next-generation oral immune-oncology drug candidate, functions as an HPK1 (hematopoietic progenitor kinase 1) inhibitor, designed to activate the immune system, particularly T cells, to induce 에볼루션 바카라 responses.
At the conference, HK inno.N presented data demonstrating that IN-122517 exhibited superior 에볼루션 바카라 efficacy in syngeneic colorectal cancer models compared to anti-PD-1 antibody monotherapy and achieved complete tumor remission when used in combination therapy. The company also reported that the candidate showed a continuous immune memory response following discontinuation of treatment. IN-122517 is currently in development with the aim of submitting an Investigational New Drug (IND) application in 2026.
HK inno.N also presented research findings on IN-207039, an EGFR degrader candidate being co-developed with Dong-A ST as a non-small cell lung cancer targeting 에볼루션 바카라 agent. IN-207039 features a differentiated mechanism that selectively degrades mutant EGFR proteins while sparing wild-type EGFR, and demonstrated potent tumor growth inhibition in an EGFR-mutant mouse model resistant to the current standard treatment, ‘osimertinib.’ The two companies have identified lead compounds and are targeting the selection of a non-clinical development candidate by 2026.
“We are building a diverse pipeline of innovative novel drugs not only through our own R&D efforts but also through co-development initiatives,” said Kim Bong-tae, head of HK inno.N’s New Drug Development Division. “With this 에볼루션 바카라 presentation, we aim to broaden collaboration opportunities with global pharmaceutical companies and research institutions,” he added.